文献速递妇科

IC期黏液性卵巢癌术后化疗的有效性

Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2019-07-04

基于美国2004至2014年国家癌症数据库的回顾性研究,纳入IC期黏液性卵巢癌患者,比较术后化疗与未化疗者的生存。532例(58.5%)接受化疗,377例(41.5%)未接受。倾向评分加权后,化疗组与未化疗组总生存无差异(调整4年率85.8% vs 86.3%,调整HR 0.88,95%CI 0.60-1.31)。外部验证队列912例同样未显示化疗与生存相关。

要点

  • 倾向评分加权后化疗与未化疗总生存无差异(调整HR 0.88,95%CI 0.60-1.31)。
  • 外部验证队列中化疗与病因特异性生存和总生存均无显著关联。

核心结论

  • IC期黏液性卵巢癌患者中接受术后化疗者不足60%,术后化疗与生存改善无关。

研究设计与样本

  • 回顾性分析美国2004至2014年Commission on Cancer认证机构全国肿瘤登记数据,纳入IC期黏液性卵巢癌接受初次手术者,比较术后化疗与未化疗,并采用多变量模型和倾向评分逆概率治疗加权(IPTW)。
  • 外部验证使用1988至2014年Surveillance, Epidemiology, and End Results Program数据。

主要发现

  • 532例(58.5%)接受术后化疗,377例(41.5%)未接受。
  • 多变量分析中,中/低分化肿瘤、大肿瘤尺寸和接受淋巴结清扫者更可能接受术后化疗,年轻女性和仅包膜破裂者更不可能接受术后化疗(均P < 0.05)。
  • IPTW后多变量分析显示化疗组与未化疗组总生存无差异(调整4年率85.8% vs 86.3%,调整HR 0.88,95%CI 0.60-1.31)。
  • 无论患者年龄、肿瘤分化、淋巴结清扫与否和亚分期组,化疗均无获益。
  • 验证队列912例(术后化疗520例[57.0%])中,术后化疗与病因特异性生存(调整HR 1.296,95%CI 0.846-1.984,P = 0.233)和总生存(调整HR 1.131,95%CI 0.849-1.508,P = 0.400)均无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between postoperative chemotherapy and survival of women with stage IC mucinous ovarian cancer (MOC). METHODS: Comprehensive nationwide tumor registry data from the Commission on Cancer-accredited facilities in the United States from 2004 to 2014 were retrospectively examined. Women with stage IC MOC who underwent primary surgery followed by postoperative chemotherapy were compared to those who did not receive. Clinico-pathological factors associated with chemotherapy use, and overall survival associated with chemotherapy use were examined with multivariable models and propensity score inverse probability of treatment weighting (IPTW). External validation was performed by examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2014. RESULTS: There were 532 (58.5%) women who received postoperative chemotherapy and 377 (41.5%) women who did not. On multivariable analysis, those with moderately-/poorly-differentiated tumors, large tumor size, and who underwent lymphadenectomy were more likely to receive postoperative chemotherapy whereas young women and those with capsule rupture alone were less likely to receive postoperative chemotherapy (all, P < 0.05). After IPTW, there was no difference in overall survival among women who received postoperative chemotherapy versus those who did not on multivariable analysis (adjusted 4-year rates: 85.8% versus 86.3%, adjusted-hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.60-1.31). Similarly, there was no benefit with chemotherapy regardless of patient age, tumor differentiation, performance of nodal dissection, and substage groups. Among 912 cases in the validation cohort (postoperative chemotherapy use, n = 520 [57.0%]), postoperative chemotherapy use was not associated with cause-specific survival (adjusted-HR 1.296, 95% CI 0.846-1.984, P = 0.233) or overall survival (adjusted-HR 1.131, 95% CI 0.849-1.508, P = 0.400). CONCLUSION: Postoperative chemotherapy was received by fewer than 60% of women with stage IC MOC, and postoperative chemotherapy was not associated with improved survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Huang Y, Zivanovic O, et al. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. Gynecol Oncol. 2019. PMID: 31279493. doi:10.1016/j.ygyno.2019.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。